certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
early production of insulin for treatment of Australian diabetics (1923) development of a tetanus vaccine (1938) development of a combined vaccine for diphtheria, tetanus and whooping cough (1953) rapid adoption and production of a polio vaccine (1956) development of a multi-purpose animal vaccine covering pulpy kidney (enterotoxemia), tetanus, black disease, malignant oedema and blackleg (1961) production of Rhesus (D) immunoglobulin to prevent haemolytic disease in newborns due to Rh factor incompatibility (1966–67) pioneering heat treatment to protect blood and plasma products from infection with HIV (1983) collaboration on development of the world's first human papillomavirus vaccine, Gardasil, building on the pioneering work by Professor Ian Frazer (1994–2005).
=== House of Representatives === In 1968, Mizell was elected to represent the 5th District in the 91st United States Congress. He defeated Democratic nominee Smith Bagley, an R.J. Reynolds Tobacco Company official, 84,905 (52.4 percent) to 77,112 (47.6 percent). The previous 5th District representative, Democrat Nick Galifianakis, was moved to the 4th District for the 1968 elections. A supporter of Richard Nixon, Mizell ran on a platform vehemently opposed to federal spending and Communism. In his first term, he spoke in favor of trade legislation. "I believe no nation in the world need fear the Trade Bill of 1970," he said, praising it for its benefits to foreign nations and American workers alike.
The allegation along with the article forces Jim's editor Edward Burgess to fire him; Jim subsequently meets Rishi at a bar, and the two go on a cocaine bender at the latter's apartment along with Dez Watkins, a man they met at the bar. Watkins gives them drugs and turns up the volume on Rishi's stereo before leaving, inciting a noise complaint that draws police to the apartment right as Jim overdoses and dies. Jim's death is later confirmed to be a murder, with Watkins revealed as an agent of Russian foreign intelligence who gave Jim cocaine laced with fentanyl.
Hyperforin may be a constituent responsible for the antidepressant and anxiolytic properties of extracts of St. John's wort. In vitro, it acted as a reuptake inhibitor of monoamines (MRI) (particularly of serotonin, norepinephrine, dopamine) and of GABA and glutamate, with IC50 values of 0.05–0.10 μg/mL for all compounds, with the exception of glutamate, which is in the 0.5 μg/mL range. In other laboratory studies, hyperforin induced cytochrome P450 enzymes CYP3A4 and CYP2C9 by binding to and activating the pregnane X receptor.
Marc Laidlaw, the writer for the Half-Life series, later said he had intended Episode Three to end the Half-Life 2 story arc, at which point he would "step away from it and leave it to the next generation". He planned an ending similar to previous games, with Freeman left in "an indeterminate space, on hold ... So one cliffhanger after another ... I expected every installment would end without resolution, for ever and ever."
Sources: en.wikipedia.org
== Clinical significance == Mice with mutant carboxypeptidase E, Cpefat, display endocrine disorders like obesity and infertility. In some strains of mice, the fat mutation also causes hyperproinsulinemia in adult male mice, but this is not found in all strains of mice. The obesity and infertility in the Cpefat mice develop with age; young mice (<8 weeks of age) are fertile and have normal body weight. Peptide processing in Cpefat mice is impaired, with a large accumulation of peptides with C-terminal lysine and/or arginine extensions. Levels of the mature forms of peptides are generally reduced in these mice, but not eliminated. It is thought that a related enzyme (carboxypeptidase D) also contributes to neuropeptide processing and gives rise to the mature peptides in the Cpefat mice. Mutations in the CPE gene are not common within the human population, but have been identified. One patient with extreme obesity (Body Mass Index >50) was found to have a mutation that deleted nearly the entire CPE gene. This patient had intellectual disability (inability to read or write) and had abnormal glucose homeostasis, similar to mice lacking CPE activity. In obesity, high levels of circulating free fatty acids have been reported to cause a decrease in the amount of carboxypeptidase E protein in pancreatic beta-cells, leading to beta-cell dysfunction (hyperproinsulinemia) and increased beta-cell apoptosis (via an increase in ER stress).
=== Biomedicine === Blood tests for lipase may be used to help investigate and diagnose acute pancreatitis and other disorders of the pancreas. Measured serum lipase values may vary depending on the method of analysis. In patients with exocrine pancreatic insufficiency, pancreatic enzyme replacement therapy (PERT) is used to replace the various enzymes that are produced by the pancreas the supplementation of pancreatic enzymes to treat. Enzyme mixtures used for PERT will include lipase, amylase, and protease.
However, sulfur dioxide added earlier in the malolactic fermentation process limits diacetyl production by inhibiting the bacteria and limiting their activity in its entirety, including the conversion of malic to lactic acid.
Platelets also promote angiogenesis and tissue regeneration to maintain overall vascular integrity by releasing growth factors like vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). Their multifunctional role displays the challenge of innovating synthetic platelets capable of effectively replicating their physiological functions.
Lurasidone, sold under the brand name Latuda among others, is an atypical antipsychotic medication used to treat schizophrenia and bipolar depression. It is taken by mouth. Common side effects include sedation, indigestion, nausea, and insomnia. At higher dosages, there is an increased risk for restlessness and movement problems. Serious side effects are valid for all atypical antipsychotics and may include the potentially permanent movement disorder tardive dyskinesia, as well as neuroleptic malignant syndrome, angioedema, and high blood sugar levels. Although lurasidone is less likely to cause high blood sugar levels in most patients, hyperosmolar hyperglycemic syndrome may occur. In older people with psychosis as a result of dementia, it may increase the risk of dying. Use during pregnancy is of unclear safety. Lurasidone was first approved for medical use in the United States in 2010, for treating schizophrenia. In 2013, it was approved in Canada and by the U.S. Food and Drug Administration (FDA) to treat bipolar depression, either as monotherapy or adjunctively with lithium or valproate. It is not FDA approved for treating manic symptoms associated with bipolar disorder despite its FDA approval for treating bipolar depression. Generic versions were approved in the United States in 2019, and became available in 2023. In 2021, it was the 193rd most commonly prescribed medication in the United States, with more than 2 million prescriptions.
Sources: en.wikipedia.org
DNA sequencing, one of the most fundamental technologies developed to study genetics, allows researchers to determine the sequence of nucleotides in DNA fragments. The technique of chain-termination sequencing, developed in 1977 by a team led by Frederick Sanger, is still routinely used to sequence DNA fragments. Using this technology, researchers have been able to study the molecular sequences associated with many human diseases. As sequencing has become less expensive, researchers have sequenced the genomes of many organisms using a process called genome assembly, which uses computational tools to stitch together sequences from many different fragments. These technologies were used to sequence the human genome in the Human Genome Project completed in 2003. New high-throughput sequencing technologies are dramatically lowering the cost of DNA sequencing, with many researchers hoping to bring the cost of resequencing a human genome down to a thousand dollars. Next-generation sequencing (or high-throughput sequencing) came about due to the ever-increasing demand for low-cost sequencing. These sequencing technologies allow the production of potentially millions of sequences concurrently. The large amount of sequence data available has created the subfield of genomics, research that uses computational tools to search for and analyze patterns in the full genomes of organisms. Genomics can also be considered a subfield of bioinformatics, which uses computational approaches to analyze large sets of biological data.
Many metering pumps are piston-driven. Piston pumps are positive displacement pumps which can be designed to pump at practically constant flow rates (averaged over time) against a wide range of discharge pressure, including high discharge pressures of thousands of psi. Piston-driven metering pumps commonly work as follows: There is a piston (sometimes called plunger), typically cylindrical, which can go in and out of a correspondingly shaped chamber in the pump head. The inlet and outlet lines are joined to the piston chamber. There are two check valves, often ball check valves, attached to the pump head, one at the inlet line and the other at the outlet line. The inlet valve allows flow from the inlet line to the piston chamber, but not in the reverse direction. The outlet valve allows flow from the chamber to the outlet line, but not in reverse. The motor repeatedly moves the piston into and out of the piston chamber, causing the volume of the chamber to repeatedly become smaller and larger. When the piston moves out, a vacuum is created. Low pressure in the chamber causes liquid to enter and fill the chamber through the inlet check valve, but higher pressure at the outlet causes the outlet valve to shut. Then when the piston moves in, it pressurizes the liquid in the chamber. High pressure in the chamber causes the inlet valve to shut and forces the outlet valve to open, forcing liquid out at the outlet. These alternating suction and discharge strokes are repeated over and over to meter the liquid.
Rick Stein's Food Heroes Christmas Special, BBC TV, December 2005. 2 half-hour episodes, also aired as a 1-hour programme. Betjeman and Me: Rick Stein's Story, August 2006 Rick Stein and the Japanese Ambassador, BBC Two, 2006 Rick Stein in Du Maurier Country, BBC Two, May 2007 Fishy Treats and Simple Eats, Japanese Food Network, Autumn 2007 Rick Stein's Mediterranean Escape, BBC Two, 8 August 2007. 6 episodes Rick Stein's Memoirs of a Seafood Chef, BBC Two, 7 January 2009 Who Do You Think You Are?, BBC TV, 16 February 2009 Rick Stein's Far Eastern Odyssey, BBC Two, July 2009. 6 episodes Rick Stein's Christmas Odyssey, BBC Two, December 2009 Rick Stein's Food of the Italian Opera, BBC HD, June 2010 Rick Stein's Cornish Christmas, BBC Two, December 2010 Rick Stein's Spain, BBC Two, July 2011. 4 episodes Rick Stein Tastes The Blues, BBC Four, November 2011 Rick Stein's Spanish Christmas, BBC Two, December 2011 Rick Stein's India, BBC Two, June 2013. 6 episodes Rick Stein's German Bite, BBC Two, August 2013 (Also referred to as The German Odyssey) Rick Stein: From Venice to Istanbul, BBC Two, August 2015. 7 episodes A Cook Abroad, BBC Two, 2 March 2015 (episode 5: Rick Stein's Australia) Rick Stein's Taste of Shanghai, BBC Two, February 2016 Rick Stein's Long Weekends, BBC Two, May 2016. 10 episodes Rick Stein's Road to Mexico, BBC Two, November 2017. 7 episodes Talking Books, BBC 2018 Rick Stein's Secret France, BBC Two, Autumn 2019. 6 episodes Pointless Celebrities, BBC One, 28 November 2020 Rick Stein's Cornwall, BBC Two, January 2021.
The C-terminal tail is not structured, therefore the mechanisms of regulation of IRS-1 by phosphorylation still remain unclear. It has been shown that TNFα causes insulin resistance and multi-site S/T phosphorylation, which results in block of interaction between IRS-1 and juxtamembrane domain peptide, thus converting IRS-1 into an inactive state. IRS-1 plays important biological function for both metabolic and mitogenic (growth promoting) pathways: mice deficient of IRS1 have only a mild diabetic phenotype, but a pronounced growth impairment, i.e., IRS-1 knockout mice only reach 50% of the weight of normal mice.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.